Loading...

TBPH THERAVANCE BIOPHARMA INC Company Mergers 8-K Filing

THRV

TBPH

THERAVANCE BIOPHARMA INC

(TBPH)

2025 8-K

Settlement Agreement

Financial Results Update

Financial Restructuring

Investor Meetings Scheduled

Investor Event Announced

Financial Update

Enrollment Complete

Settlement Agreement

Contract Renewal

Asset Acquisitions

Financial Statements

Financial Results

Q3 Earnings Report

Patent Settlement

Investor Conference

Annual General Meeting

Settlement Agreement for YU...

Settlement Agreement for YU...

Cooperation Agreement

Settlement Agreement for YU...

Investor Conferences

Termination of License Agre...

Changes to Equity Incentive...

Presentation at Needham Vir...

Appointment of James C. Kel...

Business Update and Investo...

External Links:

On May 30, 2025, Theravance Biopharma, Inc. signed an agreement to sell its royalty rights to GlaxoSmithKline for $225 million. This deal involves future royalty payments expected to start from 2029 and 2031.

AI Assistant

THERAVANCE BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.